Niveles plasmáticos de midkina en pacientes con trastorno por uso de cocaína en abstinencia

  1. Iñigo Pallardo-Fernández 1
  2. Nuria García-Marchena 2
  3. Carmen Rodríguez-Rivera 1
  4. Francisco Javier Pavón 2
  5. Carmen González-Martín 1
  6. Fernando Rodríguez de Fonseca 2
  7. Luis F. Alguacil 1
  1. 1 Universidad CEU San Pablo
    info

    Universidad CEU San Pablo

    Madrid, España

    ROR https://ror.org/00tvate34

  2. 2 Hospital Regional Universitario de Málaga
    info

    Hospital Regional Universitario de Málaga

    Málaga, España

    ROR https://ror.org/01mqsmm97

Revista:
Adicciones: Revista de socidrogalcohol

ISSN: 0214-4840

Any de publicació: 2022

Volum: 34

Número: 4

Pàgines: 273-277

Tipus: Article

DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Adicciones: Revista de socidrogalcohol

Resum

Preclinical evidence suggests that endogenous midkine could play a key modulatory role on the neurotoxic and addictive effects of different kinds of drugs of abuse, including psychostimulants. However, this hypothesis has not yet been explored in humans. As a first approach to progress in this knowledge, we have comparatively studied plasma midkine levels in 75 patients with cocaine use disorder under abstinence and 26 control subjects matched for sex, age and body mass index. Patients were further segmented into early- abstinent (up to one month of abstinence, n = 30) and late-abstinent (more than one month of abstinence, n = 45). Midkine levels were quantified in plasma samples of all the participants by enzyme-linked immunosorbent assays. Early-abstinent patients exhibited a 60% increase of midkine plasma concentration in comparison with the controls. This elevation tended to normalize upon the progression of abstinence. The results obtained demonstrate that peripheral midkine levels are closely related to cocaine use and are consistent with the idea that this cytokine could play a protective role by limiting the biological activity of psychostimulants

Referències bibliogràfiques

  • Alguacil, L. F. & Herradón, G. (2015). Midkine and pleiotrophin in the treatment of neurodegenerative diseases and drug addiction. Recent Patents on CNS Drug Discovery, 10, 28-33. doi:10.2174/1574889810666150326103916.
  • American Psychiatric Association (2000). DSM-IV-TR: Diagnostic and statistical manual of mental disorders, text revision. Washington DC: American Psychiatric Association.
  • Campbell, V. K., Anstey, C. M., Gately, R. P., Comeau, D. C., Clark, C. J., Noble, E. P.,… Gray, N. A. (2017). Urine and serum midkine levels in an Australian chronic kidney disease clinic population: An observational study. BMJ Open, 7, e014615. doi:10.1136/bmjopen-2016-014615.
  • Esnafoglu, E. & Cirrik, S. (2018). Increased serum midkine levels in autism spectrum disorder patients. International Journal of Neuroscience, 128, 677-681. doi:10.1080/00207454.2017.1408620.
  • Flatscher-Bader, T. & Wilce, P. A. (2008). Impact of alcohol abuse on protein expression of midkine and excitatory amino acid transporter 1 in the human prefrontal cortex. Alcoholism, Clinical and Experimental Research, 32, 1849-1858. doi:10.1111/j.1530-0277.2008.00754.x.
  • Fujisawa, K., Matsumoto, Y., Muramatsu, H., Shinzato, T., Hiramatsu, K., Horie, K.,… Maeda, K. (1998). Increased serum midkine levels during hemodialysis using heparin in chronic renal failure. Journal of Biochemistry, 123, 864-869. doi:10.1093/oxfordjournals.jbchem.a022017.
  • Gramage, E., Martín, Y.B., Ramanah, P., Pérez-García, C. & Herradón, G. (2011). Midkine regulates amphetamine-induced astrocytosis in striatum but has no effects on amphetamine-induced striatal dopaminergic denervation and addictive effects: functional differences between pleiotrophin and midkine. Neuroscience, 190, 307-317. doi:10.1016/j.neuroscience.2011.06.014.
  • Gramage, E., Pérez-García, C., Vicente-Rodríguez, M., Bollen, S., Rojo, L. & Herradón, G. (2013). Regulation of extinction of cocaine-induced place preference by midkine is related to a differential phosphorylation of peroxiredoxin 6 in dorsal striatum. Behavioural Brain Research, 253, 223-231. doi:10.1016/j.bbr.2013.07.026.
  • Herradón, G. & Pérez-García, C. (2014). Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: Recent progress and perspectives. British Journal of Pharmacology, 171, 837-848. doi:10.1111/bph.12312.
  • Ito, M., Oshima, Y., Yajima, S., Suzuki, T., Nanami, T., Shiratori, F.,… Shimada, H. (2019). Diagnostic impact of high serum midkine level in patients with gastric cancer. Annals of Gastroenterological Surgery, 3, 195-201. doi:10.1002/ags3.12226.
  • Jones, D. R. (2014). Measuring midkine: The utility of midkine as a biomarker in cancer and other diseases. British Journal of Pharmacology, 171, 2925-2939. doi:10.1111/bph.12601.
  • Muramatsu, T. (2011). Midkine: A promising molecule for drug development to treat diseases of the central nervous system. Current Pharmaceutical Design, 17, 410-423. doi:10.2174/138161211795164167.
  • Pathiraja, A., Marazziti, D., Cassano, G. B., Diamond, B. I. & Borison, R. L. (1995). Phenomenology and neurobiology of cocaine withdrawal: Are they related? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 19, 1021-1034. doi:10.1016/0278-5846(95)00194-8.
  • Salama, R. H., Muramatsu, H., Shimizu, E., Hashimoto, K., Ohgake, S., Watanabe, H.,… Muramatsu, T. (2005). Increased midkine levels in sera from patients with Alzheimer’s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29, 611-616. doi:10.1016/j.pnpbp.2005.01.018.
  • Salaru, D. L., Albert, C., Königsmark, U., Brandt, S., Halloul, Z., Heller, A.,… Mertens, P. R. Serum levels for midkine, a heparin-binding growth factor, inversely correlate with angiotensin and endothelin receptor autoantibody titers in patients with macroangiopathy. International Angiology, 33, 372-378.
  • Shimizu, E., Hashimoto, K., Salama, R. H., Watanabe, H., Komatsu, N., Okamura, N.,… Iyo, M. (2003). Two clusters of serum midkine levels in drug-naive patients with schizophrenia. Neuroscience Letters, 344, 95-98. doi:10.1016/s0304-3940(03)00443-9.
  • Sorrelle, N., Dominguez, A. T. A. & Brekken, R. A. (2017). From top to bottom: Midkine and pleiotrophin as emerging players in immune regulation. Journal of Leukocyte Biology, 102, 277-286. doi:10.1189/jlb.3MR1116-475R.
  • Torrens, M., Serrano, D., Astals, M., Pérez-Domínguez, G. & Martín-Santos, R. (2004). Diagnosing comorbid psychiatric disorders in substance abusers: Validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. American Journal of Psychiatry, 161, 1231-1237. doi:10.1176/appi.ajp.161.7.1231.
Fuente de los datos: Dialnet